Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Opioid Abuse Deterrence, Research, and Recovery Act of 2017
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Abuse Deterrent Access Act of 2018
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) via ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
2018 · fourth_quarter · Q4
None
Pain therapy access policy issues
Prescription drug abuse and misuse policy issues Pain therapy access policy issues
Source: Senate LDA
Prescription drug abuse policy issues Provisions related to abuse-deterrent opioid formulary placement Provisions related to abuse-deterrent opioid coverage and access in Medicare H.R. 5582, the Abuse Deterrent Access Act regarding access to abuse-deterrent opioids in Medicare S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Substance Abuse Prevention Act of 2018
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Substance Abuse Prevention Act of 2018
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse policy issues Provisions related to abuse-deterrent opioid formulary placement Provisions related to abuse-deterrent opioid coverage and access in Medicare H.R. 5582, the Abuse Deterrent Access Act regarding access to abuse-deterrent opioids in Medicare S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Stop Tampering of Prescription Pills Act of 2015
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Curb Opioid Misuse By Advancing Technology Act of 2016
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Comprehensive Addiction and Recovery Act of 2016
Client: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) · Firm: ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) via ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
2018 · third_quarter · Q3
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), the Stop Tampering of Prescription Pills Act: provisions related to approval of abuse-deterrent opioids H.R. 5127 (114th Congress), the Curb Opioid Misuse by Advancing Technology (COMBAT) Act: provisions related to encouraging the development of abuse-deterrent technology H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act: provisions related to the development of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
Prescription drug abuse policy issues Provisions related to abuse-deterrent opioid formulary placement Provisions related to abuse-deterrent opioid coverage and access in Medicare H.R. 5582, the Abuse Deterrent Access Act regarding access to abuse-deterrent opioids in Medicare S. 2789, the Substance Abuse Prevention Act of 2018 regarding access to abuse-deterrent opioids
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE